🔴 Elicio Therapeutics is trading 5.5% down today as investors weigh capital raise and trial setbacks

Elicio Therapeutics is trading 5.5% down at $2.94 as investors continue to digest the company's recent capital raise and clinical trial setbacks.

• The company recently completed a $15 million registered direct offering to fund the development of its ELI-002 7P cancer vaccine.
• Sentiment remains pressured following June's Phase 2 AMPLIFY-7P data, which missed its primary endpoint and continues to drive stock volatility.